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Research on CTLs has been booming in recent years—there
are more than 250 papers related to CD8 T-cells published
everymonth.Withsuchrapidadvancementinthisparticular
aspect of immunology alone, it is important to summarize
and report information on this hot topic in a timely and or-
ganized fashion. Although the submission window for this
issue was open for a signiﬁcantly shorter period compared
to the last issue on this topic, we received an even broader
depth of reviews on many diﬀerent aspects of CTL function
and application including some focused on the development
of vaccines against cancer and viral infections. For example,
by reviewing mechanisms of T-cell evasion by tumors, nov-
el approaches were proposed to improve the anticancer ca-
pacity of T-cells including the adoptive transfer of T-cells as
an alternative methodology to deliver tumor-associated anti-
gens and DC-associated molecules. In addition, vaccination
strategies against infectious diseases targeting CTLs and the
PD-1/PD-L1 pathway and as well as the induction of eﬀector
CTL responses in mucosal sites are also proposed. Lastly, a
new detection method of virus-speciﬁc CTLs in ﬁlovirus in-
fection and a model system reported to target both CTL and
CD4 epitopes in viral infections are also described.
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